



an Open Access Journal
Published by MDPI

CiteScore 1.4

Gout, Urate, and Crystal Deposition Disease



[mdpi.com/
journal/
gucdd](https://mdpi.com/journal/gucdd)

G-CAN

Gout Hyperuricemia and
Crystal-Associated Disease Network

Message from the Editors-in-Chief

The G-CAN (Gout, Hyperuricemia and Crystal-Associated Disease Network) launched the *Gout, Urate and Crystal Deposition Disease* open access journal with publisher MDPI in late 2022. The target audience is broad, including people interested in the epidemiology, pathophysiology, imaging, diagnosis, treatment, and outcomes of gout, and hyperuricemia, degenerative and inflammatory calcium crystal arthropathies (including calcium pyrophosphate and basic calcium phosphate crystal deposition disease). This is the only journal dedicated to the field of gout, urate biology and crystal deposition diseases. The journal will publish high-quality basic science, translational science and clinical science studies, including clinical studies, and also impactful review articles.

Editors-in-Chief

Dr. Tony Merriman
Prof. Dr. Tristan Pascart

Aims

The *Gout, Urate, and Crystal Deposition Disease* journal serves as a platform for the exchange of knowledge by publishing original research articles, reviews and short communications on gout and crystal deposition-associated disorders. Readers and authors who are particularly interested in the epidemiology, pathophysiology, imaging, diagnosis, treatment and outcomes of gout, hyperuricemia and degenerative and inflammatory calcium crystal arthropathies. In addition, the journal will appeal to readers and authors interested in crystal deposition disorders that involve not only the joint, but also renal, vascular and other extra-articular tissues. The range of investigative work presented in the journal will not only be international, but also both inter- and multidisciplinary. Major sources of published works will include clinicians such as rheumatologists, nephrologists, cardiologists, endocrinologists and orthopedists, and researchers in epidemiology, genomics, bioinformatics, other data sciences and advanced imaging.

Scope

- Gout
- Hyperuricemia and urate biology
- Inflammatory arthritis
- Degenerative joint disease
- Cartilage disease
- Rheumatology and orthopedics
- Advanced imaging
- Crystallography
- Clinical pharmacology
- Biochemistry
- Ion transport
- Epidemiology
- Genetics and genomics
- Molecular biology
- Chronic kidney disease
- Cardiovascular disease
- Podiatry and physical medicine

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

20% discount for G-CAN members

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 42.2 days after submission; acceptance to publication is undertaken in 3 days (median values for papers published in this journal in the first half of 2025)

MDPI is a member of

CASPA



STM¹

| C | O | P | E |

SPARC*
Europe



DOAJ



ORCID

Partner Society:

Gout, Hyperuricemia and Crystal Associated Disease Network (G-CAN)



Editorial Office

gucdd@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

July 2025

